People In Business NYSE 4

USA

Johnson and Johnson chief financial officer Dominic J. Caruso sells 24 July 2017

NEWS BITES - PEOPLE IN BUSINESS

Johnson and Johnson (NYSE:JNJ) Chief Financial Officer Dominic J. Caruso sold 82,591 shares worth $US11,291,478 on July 20. The selling price was $US136.72.

HTTP link to original article

https://www.sec.gov/Archives/edgar/data/200406/000122520817012818/xslF345X03/doc4.xml

Dominic J. Caruso (Reported Selling; trailing 12 months)
MonthNo. of SharesPrice, USDValue, USD
July 24, 201782,591136.7211,291,478
July 28, 201641,146125.015,143,810
Total123,737132.8216,435,288

Original news release

Source: SEC

SECTION 1 BIOGRAPHY DOMINIC J. CARUSO, CFO

In addition to his contribution to our company's overall performance, Mr. Caruso:

Drove strong financial and cash flow management, reflected by the organization meeting or exceeding its 2015 business plan for operational sales, adjusted operational EPS, and free cash flow.

Drove focus on capital allocation; clear and effective analysis of merger and acquisition activity; and initiated a $10 billion share buyback program.

Deepened relationships and external partnerships with the financial community and was actively involved in industry coalitions.

Provided strong leadership within the Finance and Procurement functions, including strengthening the talent pipeline in key roles across those functions.

Remuneration

Year:2016

Salary ($):909,500 Stock Awards ($):3,624,523

Option Awards ($):1,425,643

Non-Equity Incentive Plan Compensation($):2,758,967

Change in Pension Value and Nonqualified Deferred Compensation Earnings ($) :2,475,956

All Other Compensation ($):110,240

Total ($):11,304,829

PermID: 34413175290

SECTION 2 JOHNSON & JOHNSON SCORECARD (NYSE:JNJ):

+ Johnson & Johnson is placed 1,259/2,588 in the BSS News Bites ranking of NYSE performers in the past year, a percentile ranking of 51.

2.1 Key Financials (All figures percent)

JNJRevenue GrowthEPS GrowthOperating MarginROE
20172.68.228.623.5
2016-3.3-3.928.221.7
20144.218.528.423.4
20136.124.622.418.7

2.2 Moving Annual Return (Trailing 12 months):

JNJCloseDividendsCapital Gain %% YieldAnnual Return %
Last Traded Jul 24$US133.42$US3.249.62.712.3
1 Year ago$US121.73$US3.0528.33.231.5
2 Years ago$US94.87$US2.851.134.2
3 Years ago$US93.80$US2.6813.93.317.2
4 Years ago$US82.32$US2.4937.84.241.9

2.3 Revenue and Net Profit

DescriptionAnnual ($US B)5 years Avg ($US B)5 years CAGR %
Total Revenue71.9712.0
Operating Profit20.518.39.7
Net Profit16.514.511.3

CAGR = Compound Annual Growth Rate

2.4 Performance (All figures in %)

A track record of profits in 4 of the last 4 years

DescriptionAnnual5 years Avg
Operating Profit Margin28.625.8
Net Profit Margin23.020.4
Return on Equity23.520.8
Return on Assets11.711.0
Return on Capital Employed17.917.2

2.5 High Performance Indicators:

DescriptionValueRank In Market
Today's Turnover$US916.5 millionIn Top 2%
Interest Cover28.3In Top Quartile
Return on Assets [ROA] %11.7In Top Quartile
Return on Capital Employed [ROCE] %17.9In Top Quartile
Price/MAP2001.12In Top Quartile

2.6 Present Value of $US1000 invested in the past

PV$10001-week1-month1-year
JNJ.NYSE1,0201,0031,141
S&P 500 Index1,0061,0201,142

2.7 Trailing Price Change %

Price Change %1-Month3-Month1-Year
JNJ-1.939.299.6
Pharmaceuticals sector-1.954.46-3.05
S&P 500 Index1.23.9413.45

2.8 Market Position

Johnson & Johnson (NYSE:JNJ), NYSE's largest Pharmaceuticals company by market cap, climbed $US20.99 (or 18.4%) year to date in 2017 to close at $US135.31. This makes the stock the highest riser in the Pharmaceuticals sector which is up 8.4% in 2017. Compared with the S&P 500 Index which has risen 10.4% YTD, this is a relative price increase of 7.9%. The average daily volume of 5.7 million shares so far in 2017 was 0.8 times the average daily volume in 2016. In 2017 the market cap has jumped $US51.1 billion.

2.9 Global Rank

Rank in the S&P 500 Index [out of 502 stocks]

DescriptionValueRank
MCap (US$)364.5B6
Total Assets (US$)141.2B41
Revenue (US$)71.9B32
Net Profit (US$)16.5B9
Return on Equity %23.5120
Net Profit Margin %23.078
Price to Book17.6266
Price Earnings22.8226
Yield %2.4146
PV$1000 (1Year) US$1,141241
% Change YTD18.4150

SECTION 3 OTHER DIRECTORS OF JOHNSON & JOHNSON

Alex Gorsky, Chief Executive Officer & Chairman

Dominic J. Caruso, Chief Financial Officer

Susan L. Lindquist, Director

Mary Sue Coleman, Director

Mark B. McClellan, Director

Ronald Williams, Director

D. Scott Davis, Director

Mary C. Beckerle, Director

Ian Davis, Director

Charles Prince, Director

William D. Perez, Director

Anne M. Mulcahy, Director

A. Eugene Washington, Director

Michael H. Ullmann, Vice President

SECTION 4 JOHNSON & JOHNSON ACTIVITIES

Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. Johnson & Johnson has more than 250 operating companies. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. The Consumer segment includes a range of products used in the baby care, skin care, oral care, wound care and women's healthcare fields, as well as nutritional and over-the-counter pharmaceutical products. The Pharmaceutical segment includes products in the therapeutic areas, such as anti-infective, antipsychotic, cardiovascular, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, urology and virology. The Medical Devices and Diagnostics segment includes a range of products distributed to wholesalers, hospitals and retailers. In October 2008, the Company acquired HealthMedia, Inc. In December 2008, it acquired Omrix Biopharmaceuticals, Inc.

SECTION 5 RECENT NEWS OF JOHNSON & JOHNSON DIRECTORS

23 June 2017

Alex Gorsky of Johnson and Johnson in second quartile of NYSE CEO Scorecard for past year

Alex Gorsky's performance as CEO of Johnson and Johnson is ranked in the second quartile of BSS News Bites' NYSE performers for the past year. The shares were up 19.4% for the year ended June 23, 2017. The present value of USD1,000 (PV1000) invested on the appointment date of December 28, 2012 at close price of $US61.96 is $US2,516, for a capital gain of $US1,202 and dividend reinvested of $US314.

23 June 2017

Alex Gorsky - Johnson and Johnson updates CEO and chairman's profile

Johnson and Johnson recently released their definitive SEC filing DEF 14A. The updated profile of Alex Gorsky (56), CEO and Chairman is shown below.Mr. Gorsky, 56, was appointed as Chairman, Board of Directors in December 2012. He was named Chief Executive Officer, Chairman of the Executive Committee and joined the Board of Directors in April 2012. Mr. Gorsky began his Johnson & Johnson career with Janssen Pharmaceutica Inc. in 1988. Over the next 15 years, he advanced through positions of increasing responsibility in sales, marketing, and management. In 2001, Mr. Gorsky was appointed President of Janssen Pharmaceutical Inc., and in 2003 he was named Company Group Chairman of the Johnson & Johnson pharmaceutical business in Europe, the Middle East and Africa. Mr. Gorsky left Johnson & Johnson in 2004 to join Novartis Pharmaceuticals Corporation, where he served as head of the company s pharmaceutical business in North America. Mr. Gorsky returned to Johnson & Johnson in 2008 as Company Group Chairman for Ethicon. In early 2009, he was appointed Worldwide Chairman of the Surgical Care Group and member of the Executive Committee. In September 2009, he was appointed Worldwide Chairman of the Medical Devices and Diagnostics Group. Mr. Gorsky became Vice Chairman of the Executive Committee in January 2011. Mr. Gorsky also serves on the boards of the Travis Manion Foundation, the Congressional Medal of Honor Foundation and the National Academy Foundation.

23 June 2017

Anne M. Mulcahy - Johnson and Johnson updates director's profile

Johnson and Johnson recently released their definitive SEC filing DEF 14A. The updated profile of Anne M. Mulcahy (64), Director is shown below.Ms. Mulcahy, 64, was Chairman and Chief Executive Officer of Xerox Corporation (business equipment and services) until July 2009, when she retired as CEO after eight years in the position. Prior to serving as CEO, Ms. Mulcahy was President and Chief Operating Officer of Xerox. She also served as President of Xerox's General Markets Operations, which created and sold products for reseller, dealer and retail channels. During her career at Xerox that began in 1976, Ms. Mulcahy also served as Vice President for Human Resources with responsibility for compensation, benefits, human resource strategy, labor relations, management development and employee training; and Vice President and Staff Officer for Customer Operations, covering South America and Central America, Europe, Asia and Africa. Ms. Mulcahy has been a U.S. Board Chair of Save the Children since March 2010.

23 June 2017

Ian Davis - Johnson and Johnson updates director's profile

Johnson and Johnson recently released their definitive SEC filing DEF 14A. The updated profile of Ian Davis (66), Director is shown below.Mr. Davis, 66, is currently non-executive Chairman, Rolls-Royce Holdings plc. Mr. Davis retired from McKinsey & Company (management consulting) in 2010 as a Senior Partner, having served as Chairman and Worldwide Managing Director from 2003 until 2009. In his more than 30 years at McKinsey, he served as a consultant to a range of global organizations across the public, private and not-for-profit sectors. Prior to becoming Chairman and Worldwide Managing Director, he was Managing Partner of McKinsey s practice in the United Kingdom and Ireland. His experience included oversight for McKinsey clients and services in Asia, Europe, the Middle East and Africa, as well as expertise in the consumer products and retail industries. Mr. Davis is a Director of Teach for All, Inc., a global network of independent social enterprises working to expand educational opportunities in their nations; global energy group, BP plc.; and Majid Al Futtaim Holding LLC; and a Senior Advisor at Apax Partners, a private equity firm.

23 June 2017

William D. Perez - Johnson and Johnson updates director's profile

Johnson and Johnson recently released their definitive SEC filing DEF 14A. The updated profile of William D. Perez (69), Director is shown below.Mr. Perez, 69, is currently a Senior Advisor at Greenhill & Co., Inc. (investment banking). Mr. Perez served as President and Chief Executive Officer for the Wm. Wrigley Jr. Company (confectionary and chewing gum) from 2006 to 2008. Before joining Wrigley, Mr. Perez served as President and Chief Executive Officer of Nike, Inc. Previously, he spent 34 years with S.C. Johnson & Son, Inc., including eight years as its President and Chief Executive Officer. Mr. Perez is a Trustee for Cornell University and Northwestern Memorial Hospital.

23 June 2017

A. Eugene Washington - Johnson and Johnson updates director's profile

Johnson and Johnson recently released their definitive SEC filing DEF 14A. The updated profile of A. Eugene Washington (66), Director is shown below.Dr. Washington, 66, is currently Duke University s Chancellor for Health Affairs and the President and Chief Executive Officer of the Duke University Health System. Previously he was Vice Chancellor of Health Sciences, Dean of the David Geffen School of Medicine at UCLA; Chief Executive Officer of the UCLA Health System; and Distinguished Professor of Gynecology and Health Policy at UCLA. Prior to UCLA, he served as Executive Vice Chancellor and Provost at the University of California, San Francisco (UCSF) from 2004 to 2010. Dr. Washington co-founded UCSF s Medical Effectiveness Research Center for Diverse Populations in 1993 and served as Director until 2005. He was Chair of the Department of Obstetrics, Gynecology, and Reproductive Sciences at UCSF from 1996 to 2004. Dr. Washington also co-founded the UCSF-Stanford Evidence-based Practice Center and served as its first Director from 1997 to 2002. Prior to UCSF, Dr. Washington worked at the Centers for Disease Control and Prevention. Dr. Washington was elected to the National Academy of Sciences Institute of Medicine in 1997, where he served on its governing Council. He was founding Chair of the Board of Governors of the Patient-Centered Outcomes Research Institute, served as a member of the Scientific Management Review Board for the National Institutes of Health, and also served as Chair of the Board of Directors of both the California HealthCare Foundation and The California Wellness Foundation. Dr. Washington currently serves on the Boards of Directors of the Kaiser Foundation Hospitals and Kaiser Foundation Health Plan, Inc.

23 June 2017

Mary C. Beckerle - Johnson and Johnson updates director's profile

Johnson and Johnson recently released their definitive SEC filing DEF 14A. The updated profile of Mary C. Beckerle (62), Director is shown below.Dr. Beckerle, 62, has served as CEO and Director of Huntsman Cancer Institute since 2006 and she was appointed in 2009 to an additional key health sciences leadership role as Associate Vice President for Cancer Affairs at the University of Utah. Dr. Beckerle joined the faculty of the University of Utah in 1986, and is a distinguished professor of biology and oncological sciences, holding the Ralph E. and Willia T. Main Presidential Professorship. Dr. Beckerle has served on the NIH Advisory Committee to the Director, on the Board of Directors of the American Association for Cancer Research, as president of the American Society for Cell Biology, and as the Chair of the American Cancer Society Council for Extramural Grants. She currently serves on a number of scientific advisory boards including, the Medical Advisory Board of the Howard Hughes Medical Institute and the Scientific Advisory Boards of the National Center for Biological Sciences at the Tata Institute of Fundamental Research in India, the Mechanobiology Institute in Singapore, and the Dana Farber/Harvard Cancer Center. Dr. Beckerle held a Guggenheim Fellowship at the Curie Institute in Paris, received the Utah Governor s Medal for Science and Technology in 2001, the Sword of Hope Award from the American Cancer Society in 2004 and is an elected Fellow of the American Academy of Arts and Sciences. Dr. Beckerle was also named a National Association of Corporate Directors (NACD) Governance Fellow in 2012.

23 June 2017

D. Scott Davis - Johnson and Johnson updates director's profile

Johnson and Johnson recently released their definitive SEC filing DEF 14A. The updated profile of D. Scott Davis (65), Director is shown below.Mr. Davis, 65, served as Chairman and Chief Executive Officer of United Parcel Service, Inc. (UPS) (shipment and logistics) from 2008 to 2014, and as Chairman from 2014 to 2016. Previously, Mr. Davis held various leadership positions with UPS, primarily in the finance and accounting area, including Vice Chairman and Chief Financial Officer. Prior to joining UPS, he was Chief Executive Officer of II Morrow Inc., a developer of general aviation and marine navigation instruments. Mr. Davis is a Certified Public Accountant. He previously served on the Board of the Federal Reserve Bank of Atlanta from 2003 to 2009, serving as Chairman in 2009. Mr. Davis is a trustee of the Annie E. Casey Foundation and a member of The Carter Center Board of Councilors

23 June 2017

Mary Sue Coleman - Johnson and Johnson updates director's profile

Johnson and Johnson recently released their definitive SEC filing DEF 14A. The updated profile of Mary Sue Coleman (73), Director is shown below.Having served as President of two of the nation's largest and most prestigious public universities and having a long and decorated career in the sciences, Dr. Coleman brings to our Board a unique point of view regarding organizational management and academic research vital to a company competing in science-based industries.Dr. Coleman joined the Board of Directors in 2003 and is a member of the Audit Committee and the Science, Technology & Sustainability Committee. She is President Emerita of the University of Michigan, having served as President from August 2002 to July 2014. She also was a Professor of Biological Chemistry in the University of Michigan Medical School and a Professor of Chemistry in the University of Michigan College of Literature, Science and the Arts. From 1995 to July 2002, Dr. Coleman served as President of the University of Iowa. Prior to 1995, Dr. Coleman served as Provost and Vice President for Academic Affairs at the University of New Mexico, Vice Chancellor for Graduate Studies & Research and Associate Provost and Dean of Research at the University of North Carolina at Chapel Hill, and a member of the biochemistry faculty and an administrator at the Cancer Center of the University of Kentucky in Lexington. Elected to the National Academy of Sciences' Institute of Medicine in 1997, Dr. Coleman is a Fellow of the American Academy of Arts and Sciences and the American Association for the Advancement of Science. Dr. Coleman is a Trustee of the Gerald R. Ford Foundation, the Gates Cambridge Scholarship program, and the Mayo Clinic Foundation, and is on the Board of Directors of The Kavli Foundation.

23 June 2017

Alex Gorsky - Johnson and Johnson updates CEO and chairman's profile

Johnson and Johnson recently released their definitive SEC filing DEF 14A. The updated profile of Alex Gorsky (56), CEO and Chairman is shown below.Mr. Gorsky, 56, was appointed as Chairman, Board of Directors in December 2012. He was named Chief Executive Officer, Chairman of the Executive Committee and joined the Board of Directors in April 2012. Mr. Gorsky began his Johnson & Johnson career with Janssen Pharmaceutica Inc. in 1988. Over the next 15 years, he advanced through positions of increasing responsibility in sales, marketing, and management. In 2001, Mr. Gorsky was appointed President of Janssen Pharmaceutical Inc., and in 2003 he was named Company Group Chairman of the Johnson & Johnson pharmaceutical business in Europe, the Middle East and Africa. Mr. Gorsky left Johnson & Johnson in 2004 to join Novartis Pharmaceuticals Corporation, where he served as head of the company s pharmaceutical business in North America. Mr. Gorsky returned to Johnson & Johnson in 2008 as Company Group Chairman for Ethicon. In early 2009, he was appointed Worldwide Chairman of the Surgical Care Group and member of the Executive Committee. In September 2009, he was appointed Worldwide Chairman of the Medical Devices and Diagnostics Group. Mr. Gorsky became Vice Chairman of the Executive Committee in January 2011. Mr. Gorsky also serves on the boards of the Travis Manion Foundation, the Congressional Medal of Honor Foundation and the National Academy Foundation.

Source: www.BuySellSignals.com